4th Nov 2015 10:43
LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said it will present data on its adjuvant technology at the World Vaccine Congress in Madrid next week.
The data to be presented will support the use of adjuvant MCT in novel vaccine candidate formulations, including those for malaria and influenza.
"We have developed a portfolio of adjuvants to deliver optimised immunotherapy in allergy settings including the use of the TLR-4 adjuvant MPL in addition to MCT and this has allowed us to develop a market leading position in Europe for the treatment of seasonal allergies," said Manuel Llobet, Allergy's chief executive.
Shares in Allergy were down 0.4% to 30.125 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.